Progenics Pharmaceuticals, a New York City-based oncology and imaging company, has announced a new collaboration aimed at improving care for veterans with prostate cancer.
Progenics will work with the VA Greater Los Angeles Healthcare System (VAGLAHS) on its AI research program, giving the system full access to its existing machine learning platforms.
“Progenics’ AI research program will provide the VAGLAHS, and in the future, the entire VA, with standardized, quantitative information to improve the quality of life, care and treatment of our veterans with prostate cancer,” Mark Baker, CEO of Progenics, said in a prepared statement. “We believe that artificial intelligence can be applied successfully to automate the segmentation, classification, and quantification of tumors, thereby enabling improved treatment decisions for men with prostate cancer.”
This collaborative research will “explore novel predictive machine learning algorithms from the digital medical images and its associated clinical outcomes,” according to the statement.